ArticleACS omega2017
Imidazoles Induce Reactive Oxygen Species in
Article in ACS omega, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Rifampicin/Quercetin Nanoemulsions: Co-Encapsulation and In Vitro Biological Assessment Toward Tuberculosis Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 inAntimicrobial agents and chemotherapy · 2025Article
- Common Biological Properties ofACS infectious diseases · 2025Article
- 8-Hydroxyquinoline Series Exerts Bactericidal Activity againstACS infectious diseases · 2024Article
- Benzene Amide Ether Scaffold is Active against Non-replicating and IntracellularACS infectious diseases · 2023Article
- Mitochondrial reactive oxygen species: double agents in Mycobacterium tuberculosis infection.Current opinion in immunology · 2023Review
- TheMicroorganisms · 2023Article
- Functionalized Dioxonaphthoimidazoliums: A Redox Cycling Chemotype with Potent Bactericidal Activities againstJournal of medicinal chemistry · 2021Article
- Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action inFrontiers in cellular and infection microbiology · 2020Review
- Understanding lipidomic basis of iron limitation induced chemosensitization of drug-resistant3 Biotech · 2019Article
- Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation.Antimicrobial agents and chemotherapy · 2019Article
- Mutations in the anti-sigma H factor RshA confer resistance to econazole and clotrimazole inAccess microbiology · 2019Article
- Understanding the role of interactions between host and Mycobacterium tuberculosis under hypoxic condition: an in silico approach.BMC genomics · 2018Article
- Construction of an overexpression library forBiology methods & protocols · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Azoles are a class of antimicrobial drugs used clinically to treat yeast and fungal infections. Against pathogenic yeast and fungi, azoles act by inhibiting the activity of the cytochrome P450 Cyp51, which is involved in the synthesis of a critical component of the yeast and fungal cell membrane. Azoles have antibacterial activity, including against mycobacteria, but the basis for this activity is not well-understood. We demonstrated that imidazoles are bactericidal to
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.